Literature DB >> 11035346

Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor.

A Gossmann1, T H Helbich, S Mesiano, D M Shames, M F Wendland, T P Roberts, N Ferrara, R B Jaffe, R C Brasch.   

Abstract

OBJECTIVE: Magnetic resonance imaging enhanced with macromolecular contrast medium was used to monitor effects of angiogenesis inhibition on tumor microvascular permeability and ascites volume in an athymic rat model of human ovarian cancer. STUDY
DESIGN: Groups of 6 athymic rats implanted intraperitoneally with SKOV-3, a human ovarian cancer cell line, were treated through a 14-day course with antibody to vascular endothelial growth factor or with saline solution for control animals. Dynamic magnetic resonance imaging was performed with a 92,000-d contrast agent, albumin-(gadolinium-diethylenetriaminepentaacetic acid)(30). Vascular permeability was estimated from dynamic enhancement data that were analyzed with a unidirectional 2-compartment kinetic model.
RESULTS: Animals treated with vascular endothelial growth factor antibody accumulated significantly smaller volumes of peritoneal ascites (P <.05) and showed significantly lower magnetic resonance imaging-assayed tumor microvascular permeabilities (P <.05) than did control animals.
CONCLUSION: Magnetic resonance imaging enhanced with a macromolecular contrast agent in an athymic rat model of human ovarian cancer treated with anti-vascular endothelial growth factor antibody can be used to measure a reduction in tumor microvascular permeability, corresponding to a reduction in ascites production.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11035346     DOI: 10.1067/mob.2000.107092

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  13 in total

1.  Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.

Authors:  Setsuko K Chambers; Mary C Clouser; Amanda F Baker; Denise J Roe; Haiyan Cui; Molly A Brewer; Kenneth D Hatch; Michael S Gordon; Mike F Janicek; Jeffrey D Isaacs; Alan N Gordon; Raymond B Nagle; Heather M Wright; Janice L Cohen; David S Alberts
Journal:  Clin Cancer Res       Date:  2010-11-01       Impact factor: 12.531

2.  Magnetic resonance characterization of tumor microvessels in experimental breast tumors using a slow clearance blood pool contrast agent (carboxymethyldextran-A2-Gd-DOTA) with histopathological correlation.

Authors:  Anda Preda; Viktor Novikov; Martina Möglich; Eugenia Floyd; Karl Turetschek; David M Shames; Timothy P L Roberts; Claire Corot; Wayne O Carter; Robert C Brasch
Journal:  Eur Radiol       Date:  2005-07-13       Impact factor: 5.315

3.  Monitoring the longitudinal intra-tumor physiological impulse response to VEGFR2 blockade in breast tumors using DCE-CT.

Authors:  Keith M Stantz; Minsong Cao; Ning Cao; Yun Liang; Kathy D Miller
Journal:  Mol Imaging Biol       Date:  2011-12       Impact factor: 3.488

Review 4.  Beyond chemotherapy: targeted therapies in ovarian cancer.

Authors:  Timothy A Yap; Craig P Carden; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

Review 5.  Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis.

Authors:  Tsz-Lun Yeung; Cecilia S Leung; Kay-Pong Yip; Chi Lam Au Yeung; Stephen T C Wong; Samuel C Mok
Journal:  Am J Physiol Cell Physiol       Date:  2015-07-29       Impact factor: 4.249

6.  Vascular permeability during antiangiogenesis treatment: MR imaging assay results as biomarker for subsequent tumor growth in rats.

Authors:  Hans-Juergen Raatschen; Gerhard H Simon; Yanjun Fu; Barbara Sennino; David M Shames; Michael F Wendland; Donald M McDonald; Robert C Brasch
Journal:  Radiology       Date:  2008-03-27       Impact factor: 11.105

Review 7.  The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion.

Authors:  Michael Bradshaw; Aaron Mansfield; Tobias Peikert
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075

8.  Single-level dynamic spiral CT of hepatocellular carcinoma: correlation between imaging features and density of tumor microvessels.

Authors:  Wei-Xia Chen; Peng-Qiu Min; Bin Song; Bong-Liang Xiao; Yan Liu; Ying-Hui Ge
Journal:  World J Gastroenterol       Date:  2004-01       Impact factor: 5.742

Review 9.  Metastasis of a histologically benign choroid plexus papilloma: case report and review of the literature.

Authors:  Ye Jinhu; Dai Jianping; Ma Jun; Sun Hui; Fang Yepeng
Journal:  J Neurooncol       Date:  2007-03-27       Impact factor: 4.506

10.  Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours.

Authors:  D Checkley; J J Tessier; J Kendrew; J C Waterton; S R Wedge
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.